Stopping Accutane Safely: Washout Period, Relapse & What to Expect

Isotretinoin is an oral retinoid used for severe, recalcitrant nodular acne. It is sold under brand names such as Absorica, Claravis, Amnesteem, and Myorisa; Accutane was the original brand and was discontinued in the U.S. in 2009, though the name is still used loosely for any oral isotretinoin. This article covers stopping the oral capsule form, not topical retinoids or other acne treatments.

Editorial status: This draft was checked against current U.S. isotretinoin prescribing information, the isotretinoin Medication Guide, and the iPLEDGE REMS patient guide on August 29, 2026. Two additional citations inherited from an earlier draft (a cohort study and a procedural-timing review) could not be independently re-verified through this review's literature search and are flagged accordingly below. Medical review of this draft is still pending. Nothing here replaces an individual prescriber's decision about when a specific patient should stop.

The core answer

Current isotretinoin labeling describes a finite course of roughly 15 to 20 weeks and does not specify an end-of-course taper; treatment simply stops when the prescriber determines the course is complete, based on nodule count reduction, tolerability, or a safety event. After the last dose, patients who can become pregnant must continue pregnancy prevention and complete a pregnancy test one month later, blood donation is restricted for one month, and the Medication Guide advises against waxing, dermabrasion, and laser procedures for at least six months, while a second course is not generally started for at least two months. These intervals are independent of each other and should not be collapsed into a single "washout period."

The first question is not "do I taper?"

Isotretinoin labeling does not include a step-down dosing schedule at the end of a course. That is not the same as saying every patient stops on the same day or after reaching one universal cumulative dose. A prescriber may end treatment because the course is complete, because the acne response supports stopping, because an adverse effect changes the benefit-risk balance, because pregnancy has occurred, or for another clinical reason.

The label allows treatment to stop before the usual 15-to-20-week course when the total nodule count has fallen by more than 70%. It also states that long-term use, even at low doses, has not been studied and is not recommended. Neither instruction supports treating a cumulative dose of 120 to 150 mg/kg as an automatic finish line that overrides clinical response, tolerability, or the specific prescription written.

Post-treatment obligations run on different clocks

Source for the label- and REMS-based rows: current isotretinoin prescribing information via DailyMed, isotretinoin Medication Guide, and the iPLEDGE patient guide.

What "no taper" does and does not mean

No taper is specified because the labeled course ends outright rather than stepping down. That does not mean a patient should stop independently because the skin looks clear, a lab result seems abnormal, or a side effect becomes inconvenient. Some symptoms call for prompt prescriber contact or urgent evaluation rather than a self-managed dose change.

The current label directs discontinuation or urgent evaluation for specific problems, including pregnancy, symptoms of intracranial hypertension, serious skin reactions, pancreatitis, hearing changes, symptoms suggestive of inflammatory bowel disease, and certain visual problems. For lipid and liver abnormalities, the label uses clinical judgment language such as monitoring and discontinuing when hypertriglyceridemia cannot be controlled; it does not publish one numeric cutoff that applies identically to every laboratory and patient.

A clinician-discussion and monitoring guide

Isotretinoin labeling tells you what must happen (pregnancy testing, blood donation restrictions, procedure timing) but not what a particular course of acne, a particular set of lab values, or a particular symptom means for an individual. The table below separates what is fixed by label or REMS rule from what should be brought to a prescriber as a question, and marks the point at which a symptom is no longer a "wait and discuss" issue.

Isotretinoin stop-and-monitor conversation guide

This guide is a discussion aid, not a diagnostic tool. It does not replace an in-person evaluation, and the "escalate promptly" column reflects categories of symptoms the label already flags as reasons for discontinuation or urgent care, not a complete list of every possible isotretinoin-related complication.

Cumulative dose matters, but it is not a non-negotiable number

Older practice often treats 120 to 150 mg/kg as a required cumulative target before stopping. A cohort study using U.S. commercial insurance claims, reportedly covering just under 20,000 patients who completed at least four months of isotretinoin with at least a year of follow-up, found that higher cumulative dose was associated with lower rates of relapse and retrial with isotretinoin, but that among patients already above roughly 120 mg/kg, a higher maximum daily dose was not associated with further reductions in relapse. The authors reportedly concluded that daily dosing can be individualized to tolerability and treatment goals once adequate cumulative exposure is reached.

This is an observational claims-based study, not a randomized stopping trial, and weight in claims data of this kind is typically estimated from population averages rather than measured directly, which limits precision. The specific patient count, percentages, and follow-up figures in this section are carried from an earlier draft's citation and were not independently re-confirmed in this review; an editor should verify them against the original paper, available via PMC, before publication. Pending that check, the safest reading is that cumulative dose is one factor associated with relapse risk in this population, not that it establishes a fixed biological threshold or overrides an individual patient's response and tolerability.

Relapse is not one outcome

Reporting from that same cohort described a substantial minority of patients receiving another systemic acne treatment after isotretinoin, a smaller subset receiving another isotretinoin course specifically, and a median time to retreatment measured in months rather than weeks among those retreated. As above, these exact figures require verification against the primary source before they are published as confirmed numbers.

Even if confirmed, "needed another systemic treatment" is not the same as "the first course failed." Claims data record prescriptions, not standardized lesion counts, patient-reported severity, or the clinical reasoning behind a new prescription. A few new comedones treated topically and a return of severe nodular acne are different clinical events that a claims database cannot easily distinguish.

Relapse-response matrix

The two-month labeled interval before a second course exists partly because improvement can continue after a 15-to-20-week course ends. Starting another course immediately risks mistaking ongoing improvement for treatment failure.

Laboratory follow-up is individualized

The label requires fasting lipid and liver function testing before treatment and monitoring during treatment. It does not specify one fixed post-treatment testing schedule for every patient.

Repeat testing after stopping may be reasonable when prior results were abnormal, symptoms persist, another medication or condition could affect the same values, or the prescriber wants to document resolution. A course with normal monitoring throughout is a different situation from stopping because of severe hypertriglyceridemia or liver enzyme elevation, which needs a clinician-directed follow-up plan rather than a fixed "wait eight weeks" assumption.

Cosmetic procedures: label rule versus evolving practice

The current Medication Guide advises against waxing, dermabrasion, or laser procedures during treatment and for at least six months after stopping, because of scarring risk. That is the patient-facing label instruction and the most conservative position.

A 2017 systematic review and expert consensus, reportedly reflecting dermatology specialty input, argued that for several less invasive procedures, including superficial chemical peels, standard cutaneous surgery, and some laser modalities, the evidence did not support a blanket delay; it reportedly did not extend that reasoning to mechanical dermabrasion or fully ablative laser treatment. As with the cohort study above, the specific scope of this consensus should be re-checked against the original paper, available via PubMed, before being cited as settled guidance.

These two sources do not fully agree, and that disagreement itself is the useful finding: the label sets a uniform six-month floor for essentially all listed procedures, while more recent specialty consensus has questioned that floor for a subset of lower-risk procedures without abandoning it for higher-risk ones like dermabrasion. A patient considering a procedure should give the treating clinician the exact isotretinoin stop date and the exact procedure planned, rather than relying on "six months" or a remembered abstract as self-clearance.

What to keep doing after the last capsule

• Complete the iPLEDGE and pregnancy-testing requirements that apply to you.
• Do not donate blood for one month.
• Do not share or reuse leftover capsules.
• Follow the dispensed skin-care instructions while dryness or sensitivity persists.
• Ask before restarting irritating topical products; there is no universal label-based restart day.
• Contact the prescriber if acne returns, rather than restarting leftover isotretinoin on your own.
• Tell any clinician planning waxing, dermabrasion, laser treatment, or another skin procedure exactly when treatment ended.

Evidence boundaries

Established by current labeling: no end-of-course taper is specified; pregnancy prevention and testing continue for one month for patients who can become pregnant; blood donation is restricted for one month; a second course requires at least two months off therapy when warranted; and cosmetic procedures should be avoided for at least six months per the Medication Guide.

Plausible but requiring verification before being treated as settled: the specific relapse and retrial percentages and the specific cumulative-dose findings attributed to a 2025 cohort study, and the specific procedure-by-procedure consensus attributed to a 2017 systematic review. Both are flagged above with links for an editor to confirm against the primary papers.

Not established by anything reviewed here: that isotretinoin tapers naturally through fat storage in a way that changes stopping practice; that all adverse effects resolve on a fixed timeline; that every patient needs post-treatment lab testing; that cumulative dose alone predicts relapse for an individual; or that multiple courses carry no cumulative risk of their own.